CJC-1295 and Ipamorelin are GH secretagogues studied for their synergistic stimulation of growth hormone secretion, IGF-1 production, and anabolic tissue effects. Physician-reviewed. Prescription required.
CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) designed to stimulate endogenous growth hormone release. Its main target is the Growth Hormone-Releasing Hormone Receptor on pituitary somatotroph cells. Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release with minimal effect on cortisol or prolactin.
Used in combination, CJC-1295 and Ipamorelin produce synergistic GH pulsatility through complementary mechanisms, supporting anabolic effects, body composition, and recovery. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| GHRH receptor activation | Stimulates GH secretion |
| cAMP/PKA signaling | Drives hormone release |
| Amplified GH pulsatility | Physiologic hormone rhythm |
| IGF-1 production | Anabolic and regenerative effects |
| GH gene transcription | Increased GH synthesis |
| Mechanism | Biological Effect |
|---|---|
| Ghrelin receptor (GHSR1a) activation | Stimulates GH release |
| PLC/IP3/Ca²⁺ signaling | Triggers pituitary hormone secretion |
| Enhanced GH pulse amplitude | Physiologic hormone rhythm |
| Increased IGF-1 production | Anabolic and regenerative effects |
| Hypothalamic modulation | Reduced somatostatin inhibition |
| High receptor selectivity | Minimal cortisol/prolactin release |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with Performance Blend protocol candidates in clinical practice:
GH Optimization
Individuals with confirmed or suspected GH decline seeking physician-supervised secretagogue therapy.
Body Composition
Individuals pursuing physician-reviewed lean mass and fat metabolism support.
Recovery & Sleep
High-output individuals seeking GH-mediated recovery and sleep architecture support.
Longevity Protocol
Individuals with existing longevity protocols adding physician-reviewed GH secretagogue therapy.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
CJC: 1–2 mg/week; Ipamorelin: 200–300 mcg/day
Administration
Subcutaneous injection
Duration
12–24 weeks (physician-determined)
Frequency
Daily or 5x/week (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.